









Mercado
/
Acciones
/
nasdaq-imnm
/

Immunome Inc

IMNM

10.300USD

+0.350+3.52%

Cierre 08/22, 16:00（ET）Cotizaciones retrasadas 15 min

896.23MCap. mercado

PérdidaP/E TTM



Immunome Inc

10.300

+0.350+3.52%

Descripción general Compañía Finanzas

Immunome, Inc. is a biotechnology company engaged in developing targeted cancer therapies. The Company's portfolio pursues each target with a modality appropriate to its biology, including immunotherapies, radioligand therapies and Antibody-Drug Conjugates (ADCs). Its memory B cell hybridoma technology allows for the screening and functional characterization of novel antibodies and targets. Its programs include Oncology (IMM-ONC-01), LU FAP, and SARS-CoV-2 (IMM-BCP-01). The oncology program is an antibody (IMM-ONC-01) against interleukin-38 (IL-38) a novel immune modulator for the treatment of various solid tumors. Its Targeted Effector platform uses small molecule ligands to selectively deliver drug payloads to diseased cells. It also operates AL102 and related drug candidate AL101. AL102 is an investigational small molecule gamma secretase inhibitor being evaluated in the Phase III for the treatment of desmoid tumors. AL102 is a potential once-daily oral treatment for desmoid tumors.

Información de la empresa

Símbolo de cotizaciónIMNM

Nombre de la empresaImmunome Inc

Fecha de salida a bolsaOct 02, 2020

Director ejecutivoDr. Clay B. Siegall, Ph.D.

Número de empleados118

Tipo de seguridadOrdinary Share

Fin del año fiscalOct 02

Dirección18702 N. Creek Parkway

CiudadBOTHELL

Bolsa de valoresNASDAQ Capital Market Consolidated

PaísUnited States of America

Código postal98011

Teléfono16103213700

Sitio Webhttps://immunome.com/

Símbolo de cotizaciónIMNM

Fecha de salida a bolsaOct 02, 2020

Director ejecutivoDr. Clay B. Siegall, Ph.D.

Ejecutivos de la empresa

Nombre

Nombre/Posición

Posición

Accionistas

Cambio

Dr. Clay B. Siegall, Ph.D.

Chairman of the Board, President, Chief Executive Officer

806.74K

+20.47%

Mr. Philip R. Wagenheim

Director

406.15K

+3.44%

Mr. Isaac Barchas, J.D.

Lead Independent Director

92.21K

-24.22%

Mr. Max Rosett

Chief Financial Officer

47.48K

+139.10%

Mr. Jean-Jacques Bienaime ,

Independent Director

36.41K

+15.92%

Dr. Jack Higgins, Ph.D.

Chief Scientific Officer

18.73K

+38.44%

Ms. Sandra G. Stoneman

Chief Legal Officer, General Counsel, Corporate Secretary

Dr. Phil Tsai

Chief Technical Officer

Dr. Sandra M Swain, M.D.

Independent Director

Dr. Bob Lechleider, M.D.

Chief Medical Officer

Nombre

Nombre/Posición

Posición

Accionistas

Cambio

Dr. Clay B. Siegall, Ph.D.

Chairman of the Board, President, Chief Executive Officer

806.74K

+20.47%

Mr. Philip R. Wagenheim

Director

406.15K

+3.44%

Mr. Isaac Barchas, J.D.

Lead Independent Director

92.21K

-24.22%

Mr. Max Rosett

Chief Financial Officer

47.48K

+139.10%

Mr. Jean-Jacques Bienaime ,

Independent Director

36.41K

+15.92%

Dr. Jack Higgins, Ph.D.

Chief Scientific Officer

18.73K

+38.44%

Desglose de ingresos

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

Sin datos

Por regiónUSD

Nombre

Ganancia

Proporción

United States

2.93M

0.00%

Por negocio

Por región

Sin datos

Estadísticas de accionistas

Actualizado: mar., 19 de ago

Accionistas

Tipos de accionistas

Accionistas

Proporción

T. Rowe Price Investment Management, Inc.

9.51%

Fidelity Management & Research Company LLC

7.09%

BlackRock Institutional Trust Company, N.A.

5.94%

Redmile Group, LLC

5.60%

Enavate Sciences GP, LLC

5.48%

Otro

66.39%

Accionistas

Proporción

T. Rowe Price Investment Management, Inc.

9.51%

Fidelity Management & Research Company LLC

7.09%

BlackRock Institutional Trust Company, N.A.

5.94%

Redmile Group, LLC

5.60%

Enavate Sciences GP, LLC

5.48%

Otro

66.39%

Tipos de accionistas

Accionistas

Proporción

Investment Advisor

43.04%

Investment Advisor/Hedge Fund

24.45%

Hedge Fund

12.05%

Corporation

8.25%

Research Firm

5.75%

Individual Investor

1.69%

Venture Capital

0.89%

Bank and Trust

0.31%

Pension Fund

0.20%

Otro

3.36%

Participación institucional

Actualizado: mar., 1 de jul

Periodo del informe

Número de instituciones

Acciones mantenidas

Proporción

Cambio

2025Q2

326

85.20M

99.48%

+13.79M

2025Q1

320

89.38M

113.71%

+17.13M

2024Q4

278

64.18M

84.45%

+3.64M

2024Q3

252

62.39M

103.49%

+7.38M

2024Q2

228

58.25M

97.90%

+16.13M

2024Q1

182

46.83M

84.41%

+22.74M

2023Q4

113

32.29M

78.79%

+19.76M

2023Q3

6.26M

40.47%

+930.23K

2023Q2

5.83M

36.98%

+582.43K

2023Q1

4.18M

34.54%

-644.30K

Actividad de los accionistas

Nombre

Acciones mantenidas

Proporción

Cambio

Cambio %

Fecha

T. Rowe Price Investment Management, Inc.

7.55M

8.68%

+2.05M

+37.36%

Mar 31, 2025

Fidelity Management & Research Company LLC

3.89M

4.47%

-26.90K

-0.69%

Mar 31, 2025

BlackRock Institutional Trust Company, N.A.

5.11M

5.87%

+1.37M

+36.49%

Mar 31, 2025

Redmile Group, LLC

5.36M

6.16%

+533.16K

+11.04%

Mar 31, 2025

Enavate Sciences GP, LLC

4.77M

5.48%

Mar 31, 2025

Point72 Asset Management, L.P.

4.36M

5.01%

+3.67M

+533.09%

Mar 31, 2025

The Vanguard Group, Inc.

4.29M

4.93%

+1.29M

+43.20%

Mar 31, 2025

EcoR1 Capital, LLC

4.08M

4.69%

+200.00K

+5.16%

Mar 31, 2025

Opaleye Management Inc.

3.55M

4.08%

+1.51M

+74.02%

Mar 31, 2025

PRIMECAP Management Company

3.41M

3.92%

+3.13M

+1115.71%

Mar 31, 2025

ETFs relacionados

Actualizado: mié., 6 de ago

Nombre

Proporción

Tema Oncology ETF

1.65%

iShares Genomics Immunology and Healthcare ETF

1.64%

WisdomTree BioRevolution Fund

1.01%

Virtus LifeSci Biotech Clinical Trials ETF

0.86%

ALPS Medical Breakthroughs ETF

0.55%

SPDR S&P Biotech ETF

0.2%

iShares Micro-Cap ETF

0.15%

Direxion Daily S&P Biotech Bull 3X Shares

0.13%

iShares Russell 2000 Growth ETF

0.05%

iShares US Tech Breakthrough Multisector ETF

0.04%

Tema Oncology ETF

Proporción1.65%

iShares Genomics Immunology and Healthcare ETF

Proporción1.64%

WisdomTree BioRevolution Fund

Proporción1.01%

Virtus LifeSci Biotech Clinical Trials ETF

Proporción0.86%

ALPS Medical Breakthroughs ETF

Proporción0.55%

SPDR S&P Biotech ETF

Proporción0.2%

iShares Micro-Cap ETF

Proporción0.15%

Direxion Daily S&P Biotech Bull 3X Shares

Proporción0.13%

iShares Russell 2000 Growth ETF

Proporción0.05%

iShares US Tech Breakthrough Multisector ETF

Proporción0.04%

Dividendos

Un total de 0.00 USD se ha distribuido en dividendos durante los últimos 5 años.

Fecha

Dividendos

Fecha de registro

Fecha de pago

Fecha ex-dividendo

Sin datos

División de acciones

Fecha

Tipo

Relación

Sin datos

Fecha

Tipo

Relación

Sin datos

KeyAI

